Welcome to our dedicated page for MindWalk Holdings SEC filings (Ticker: HYFT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MindWalk Holdings Corp. (NASDAQ: HYFT) files as a foreign private issuer in the United States and provides its regulatory disclosures primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings offer detailed information on the company’s Bio-Native AI business, financial position and capital markets activities.
On this page, users can access MindWalk’s Form 20-F, which includes audited financial statements prepared under IFRS, risk factor discussions and descriptions of its HYFT and LensAI platform. The company’s Form 6-K filings cover a range of topics, including quarterly earnings releases, pro forma condensed consolidated financial information, statements of executive compensation, reports of voting results and press releases that are incorporated by reference into its registration statements.
MindWalk has also filed 6-K reports describing a Sales Agreement with JonesTrading Institutional Services LLC for an at-the-market equity offering facility under an effective Form F-3 shelf registration statement. Other filings reference a share repurchase program authorized by the board of directors and the classification of certain operations as discontinued following the sale of its Netherlands business.
Through this SEC filings page, Stock Titan surfaces real-time updates from the EDGAR system and pairs them with AI-powered summaries that help explain the contents of lengthy documents. Users can quickly locate MindWalk’s annual report (Form 20-F), interim updates furnished on Form 6-K, and information incorporated into Forms F-3 and S-8. Filings related to equity offerings, executive compensation and program-level financial reporting can be reviewed with AI-generated highlights that clarify key points without replacing the underlying source documents.
MindWalk Holdings Corp. reported recent insider activity mirrored from Canada’s SEDI system. During March 18–27, 2026, insiders Tom Lynch and Scott Areglado acquired a combined 66,500 common shares in open-market purchases, deploying $77,024 at an average price of $1.1583 per share over three trading days.
Lynch bought 40,000 shares and now holds 41,026 common shares, or 0.09% of outstanding shares, while Areglado bought 26,500 shares and now holds 26,500 common shares, or 0.06% of outstanding shares. The report also highlights previously granted restricted stock units: 225,000 RSUs to Lynch and 185,000 RSUs to Areglado, each expiring on 2029-10-29. MindWalk notes it is exempt from Section 16 reporting and is providing this update voluntarily for U.S. investors.
MindWalk Holdings Corp. furnished a Form 6-K to share insider trading data reported on Canada’s SEDI system for March 16–20, 2026. Two insiders, Dirk M.H. Van Hyfte and Ingrid M.H. Brands, bought a combined 60,000 common shares in open-market NASDAQ trades, deploying $73,238 at an average price of $1.2178 per share.
Each insider, through vehicles Charmquark EEN and Charmquark TWEE, acquired 30,000 shares, increasing their respective holdings from 1,828,365 to 1,858,365 shares, representing 3.98% of outstanding shares each. The company notes it is exempt from U.S. Section 16 filing requirements and is providing this SEDI-based information voluntarily.
MindWalk Holdings Corp. reported strong top-line growth while remaining loss-making as it pivots to a software-led AI model. Revenue reached $4.2M for the quarter and $11.4M for the nine months ended January 31, 2026, up about 52% and 45% from a year earlier, driven mainly by Canadian B-cell project work.
Quarterly gross margin was 59%, above the company’s historical 48–57% range, with quarterly gross profit of $2.5M. Operating expenses fell sharply versus the prior-year quarter that included a large asset impairment, reducing net loss to $3.9M from $21.5M. For the nine months, net loss was $10.1M, improved from $28.1M.
Cash was $14.1M as of January 31, 2026, and management believes this is sufficient to fund operations for at least one year. Results reflect the shift toward recurring, HYFT- and LensAI-driven revenue, investment in R&D and commercialization, and the divestiture of IPA Europe B.V., which generated $10.2M USD in net proceeds.
MindWalk Holdings Corp. reported strong top-line growth for Q3 fiscal 2026 while remaining loss-making. Revenue reached $4.2 million, up 52% from $2.7 million a year earlier, marking a third consecutive quarter of year-over-year growth. US revenue doubled to $2.6 million, and gross margin for the quarter was 59%, with year-to-date gross margin improving to 58% from 53%.
The company posted a Q3 net loss from continuing operations of $3.9 million, compared with a $22.0 million loss in the prior-year quarter that included a $21.2 million impairment. For the first nine months, revenue rose to $11.4 million from $7.9 million, while the net loss from continuing operations was $11.2 million. Cash and equivalents were $14.2 million as of January 31, 2026, up from $10.8 million at the start of the period, helped by proceeds from the sale of its Europe B.V. business.
Commercially, MindWalk signed its first one-year LensAI™ platform contract with its largest enterprise AI client, creating its first contracted, recurring platform revenue stream. The company also launched its B cell Llama™ nanobody discovery platform and advanced pipeline programs in dengue, GLP-1, and influenza toward further preclinical data.
MindWalk Holdings Corp. introduced B Cell Llama™, a new platform to discover VHH nanobodies, the single‑domain antibody fragments used in bispecific antibodies, multispecific drugs, and CAR‑T cell therapies. The platform extends the company’s existing B Cell Select® technology into llama‑derived antibodies.
A peer‑reviewed study in ACS Biomacromolecules underpins the launch, showing multivalent VHH formats achieved sub‑nanomolar potency, restored activity against resistant variants, and suggested a potential immune‑priming effect. The work also showed that strong binding alone did not guarantee functional activity, supporting MindWalk’s LensAI™ focus on function‑based candidate selection.
The company positions B Cell Llama™ within a broader bio‑native AI strategy that already supports programs in dengue, universal influenza, GLP‑1 and longevity therapeutics, ALK‑1 oncology and rare disease, and other nanobody therapeutics, while holding first rights to commercialize jointly developed intellectual property from the collaboration.
MindWalk Holdings Corp. announced it will report financial results for its third quarter of fiscal year 2026 on March 12, 2026. The company will issue a press release before holding a webcasted earnings conference call at 10:30 AM Eastern Time that includes a management presentation and Q&A.
The live webcast and replay will be accessible through the Events section of MindWalk’s investor relations website. Dial-in numbers are provided for U.S. and Canadian participants, and the company encourages listeners to review its periodic reports and risk factor discussions on SEDAR+ and the SEC’s website.
MindWalk Holdings Corp. filed a Form 6-K highlighting a new application of its proprietary HYFT® technology to detect “functional adjacency” in drug discovery. Functional adjacency means different molecules can deliver the same biological effect even when their sequences look unrelated, which can affect competition, intellectual property, and asset valuation.
Using HYFT in influenza, MindWalk reports finding a conserved biological “signature” that remains stable despite significant genetic changes, supporting its approach to designing broader vaccine targets. The company positions HYFT as part of a broader data and biological reasoning platform intended to help pharmaceutical and biotechnology organizations assess functional competitors, IP exposure, and portfolio risk, and to inform licensing, M&A diligence, and R&D prioritization.
MindWalk Holdings Corp. filed a report highlighting a new scientific discovery that supports its drug discovery platform. The company has identified and validated monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein linked to amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and certain forms of Alzheimer’s disease. The work shows the platform can distinguish toxic protein conformations from healthy ones with structural precision and tie these findings to bio-native wet-lab validation. MindWalk notes that this discovery provides external, client-driven validation of its platform and reinforces its role as a discovery partner for complex neurodegenerative programs. The full study is available as a preprint on bioRxiv under the title “Rational Generation of Monoclonal Antibodies and Intrabodies Selective for Pathogenic TDP-43.”
MindWalk Holdings Corp. filed a report highlighting new progress in its universal influenza program. Using its patented HYFT Deep Data technology and LensAI platform, the company reports finding a stable functional constraint in influenza biology that appears to persist beneath changing viral genetic sequences. This HYFT-defined pattern was observed across human influenza A, including H3N2 and H3N2 subclade K, avian H5, H7, H9, swine-origin H1N1, and influenza B Victoria and Yamagata lineages.
MindWalk describes this constraint as an evolutionary requirement the virus must satisfy for infection, positioning it as a potential target for rational vaccine design. The company plans to advance the influenza program through additional pre-clinical validation and IND-enabling work in a dedicated portfolio, then pursue out-licensing or strategic development partnerships with global pharmaceutical companies, while also exploring strategic investments and other financing alternatives related to the program.
MindWalk Holdings Corp. filed a Form 6-K as a foreign private issuer, furnishing updated quarterly information for investors. The filing includes Management’s Discussion and Analysis and Condensed Interim Consolidated Financial Statements for the three and six months ended October 31, 2025 and 2024, giving more detail on the company’s recent operating and financial performance.
The filing also states that Exhibits 99.1 and 99.2 are incorporated by reference into MindWalk’s existing registration statements on Form S-8 and Form F-3, which relate to previously registered securities. In addition, CEO and CFO certifications pursuant to Canadian regulations are provided as Exhibits 99.3 and 99.4, and the report is signed on behalf of the company by Chief Executive Officer Jennifer Bath.